Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing. New data suggest patients who receive a diagnosis of chronic lymphocytic ...

Abbvie ((ABBV)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...

Chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) is rare, making it difficult to differentiate from other types of lymphoma. A new study helps explain key unique traits. Chronic lymphocytic ...

Conditional survival is the probability that a patient with a given disease will survive an additional number of years based on the fact that he or she has already survived a specific number of years.

The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca; Eli Lilly and Company) for third-line or later treatment in adults with chronic lymphocytic ...